GBP2 and colorectal cancer: GBP2’s paclitaxel sensitization in colorectal cancer suggests its upregulation could guide adjuvant therapy, monitored via drug sensitivity screens, tumor biopsies, or circulating tumor DNA analysis, optimizing therapeutic outcomes [35].